LabCorp to Offer BRCAssureSM Breast Cancer Mutation Tests

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 2, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the nationwide availability of a suite of tests to identify patients with BRCA mutations who are at increased risk for breast, ovarian and other cancers.

LabCorp Announces the Availability of a 4th Generation HIV Assay to Allow the Earlier Detection of Acute HIV Infection

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 6, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the availability of a 4 th generation HIV antigen/antibody combination assay and a new diagnostic algorithm that improves screening for HIV infection.

LabCorp Prices $400 Million in 2.50% Senior Notes Due 2018 and $300 Million in 4.00% Senior Notes Due 2023

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 29, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) announced today that it has priced its offering of $700 million in senior notes. The offering consists of two tranches: $400 million aggregate principal amount of 2.50% Senior

LabCorp Announces Proposed Sale of Senior Notes

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 29, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in two tranches with maturities of 5 and 10 years (the

Garheng Kong Named to LabCorp® Board of Directors

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 28, 2013-- Laboratory Corporation of America ®  Holdings (LabCorp ® ) (NYSE:LH) today announced that Garheng Kong, MD, PhD, has been appointed to its Board of Directors, effective December 1, 2013. “We are delighted that Garheng has accepted our invitation

Labcorp to offer new FDA-approved companion diagnostic for colorectal cancer

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 25, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the nationwide availability of QIAGEN’s therascreen ® KRAS RGQ PCR Kit, a new FDA -approved companion diagnostic for certain colorectal cancer patients.

Laboratory Corporation of America® Holdings Announces 2013 Third Quarter Results

Revenue of $1.46 billion , up 3.0% Volume growth of 5.1% Diluted EPS of $1.63 Non-GAAP Adjusted EPS Excluding Amortization of $1.80 Repurchased $288 million of stock, representing 2.9 million shares 2013 Guidance updated for revenue growth of approximately 3% and Adjusted EPS Excluding Amortization

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 1, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 12, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that for the period of September 12, 2013 to March 11, 2014 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 3, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that David P. King , Chairman and Chief Executive Officer, is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York, NY .